Analyser av Isofol Medical

Isofol Medical: Discontinuing coverage - DNB

We have discontinued coverage of Isofol Medical. Our last published view, fair value range and estimates should no longer be relied upon

DNB • 13 Aug 2023 12:40

Isofol Medical: Redeye ceases coverage - Redeye

Redeye ceases its current coverage of Isofol Medical due to the end of the contractual period.

Redeye • 01 Mar 2023 07:47

Isofol Medical Q4 2022: Uncertain future - Redeye

Redeye comments on Isofol Medical’s Q4 2022 report after shareholders voted against the board’s proposal to distribute excess cash as a divi...

Redeye • 22 Feb 2023 11:52

Isofol Medical: Board proposes liquidation - Redeye

Redeye comments on Isofol’s board proposing a liquidation of the company after considering different strategic alternatives.

Redeye • 20 Jan 2023 08:01

Isofol Medical Q3 2022: Clearer path ahead expected in late Q1 2023e - Redeye

Redeye comments on Isofol’s Q3 2022 report, and we expect the company to communicate a clearer path ahead in late Q1 2023e.

Redeye • 11 Nov 2022 13:08

Isofol Medical Undefined future - DNB

After the previously announced setback regarding the AGENT study, the Q2 report was largely in line with our expectations.

DNB • 24 Aug 2022 15:45

Isofol Q2 2022: Uncertain path forward - Redeye

Redeye comments on Isofol’s Q2 2022 report, roughly three weeks after the company communicated that its phase III AGENT trial failed to reac...

Redeye • 23 Aug 2022 13:48

Isofol Medical: AGENT phase III trial fails - DNB

Isofol Medical announced that the phase III trial AGENT had failed to reach its primary and most important secondary endpoints.

DNB • 05 Aug 2022 08:24

Isofol Medical: AGENT did not reach ORR and PFS endpoints with statistical significance - Redeye

Redeye is disappointed by Isofol’s phase III AGENT trial failing to meet its primary ORR and key secondary PFS endpoints with statistical si...

Redeye • 04 Aug 2022 11:19

Isofol Medical: Approaching AGENT read-out - DNB

In our view, the Q1 report was a non-event, with the results broadly in line with our estimates.

DNB • 17 May 2022 07:35

Isofol Q1 2022: AGENT’s mission enters its final stages - Redeye

Redeye comments on Isofol’s Q1 2022 report, with the company closing in on critical AGENT top-line data.

Redeye • 13 May 2022 07:43

Isofol Medical: Game On - Redeye

Redeye is encouraged by Isofol starting analysis of AGENT data, with top-line data some two to four months away.

Redeye • 25 Apr 2022 10:32

Isofol Medical: Waiting for AGENT read-out - DNB

Isofol Medical released its Q4 report on 24 February.

DNB • 02 Mar 2022 07:35

Isofol Medical Q4 2021: AGENT on track for top-line data in H1 2022 - Redeye

Redeye comments on Isofol’s Q4 2021 report, with the company going into a critical period.

Redeye • 24 Feb 2022 16:21

Isofol Medical: Potential approval still possible - DNB

Late last Friday, Isofol announced that the 300 PFS events triggering the analysis of the data of the ongoing phase III study will not be re...

DNB • 07 Dec 2021 08:14

Isofol Medical Intensifying precommercial activities - DNB

Isofol Medical reported a Q3 operating loss of SEK52m, fairly in line with our forecast loss of SEK49m.

DNB • 15 Nov 2021 07:50

Isofol Medical: Shifting focus from clinical to commercial development - DNB

Isofol Medical reported a Q2 operating loss of cSEK45m, slightly better than our expected loss of cSEK51m.

DNB • 25 Aug 2021 09:28

Isofol Medical Q2’21: Funding Completed in Run-Up to Crucial Read-out - Redeye

Redeye views the Q2 update on the ongoing AGENT trial as positive.

Redeye • 25 Aug 2021 09:22

Börskollen

För dig med koll på börsen